Xtl Biopharmaceuticals (XTLB) Profit After Tax (2009 - 2024)
Xtl Biopharmaceuticals (XTLB) posted quarterly Profit After Tax of $448000.0 for Q4 2024, up 133.68% year-on-year from $191711.7 in Q1 2024, and down 78.14% on a QoQ basis from $2.0 million in Q3 2024.
Xtl Biopharmaceuticals (XTLB) Profit After Tax (2009 - 2024) Analysis & Trends
Xtl Biopharmaceuticals (XTLB) has reported Profit After Tax for 16 consecutive years, with $448000.0 the latest figure, recorded in Q4 2024.
- Quarterly Profit After Tax rose 133.68% year-over-year to $448000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $2.3 million (up 241.84% YoY) and the FY2025 annual result came in at -$759000.0, down 416.25% from the prior year.
- Profit After Tax declined to $448000.0 in Q4 2024 per XTLB's latest filing, from $2.0 million in the prior quarter.
- Over the last five years, Profit After Tax for XTLB reached as high as $4.8 million in Q4 2020 and fell as low as -$1.8 million in Q4 2021.
- A 5-year average of -$97200.0 and a median of -$534000.0 in 2023 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2020 — Profit After Tax jumped 405.05% — and 2023, when it sank 281.62%.
- Year by year, Profit After Tax stood at $4.8 million in 2020, then sank by 136.75% to -$1.8 million in 2021, then rose by 13.57% to -$1.5 million in 2022, then gained by 13.36% to -$1.3 million in 2023, then soared by 133.68% to $448000.0 in 2024.
- According to Business Quant data, Profit After Tax over the past three periods registered $448000.0, $2.0 million, and -$704000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Xtl Biopharmaceuticals | 2.60 Bn | 2.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 448,000.00 |
| Sep 30, 2024 | 2.05 Mn |
| Jun 30, 2024 | -704,000.00 |
| Mar 31, 2024 | 485,000.00 |
| Dec 31, 2023 | -1.33 Mn |
| Sep 30, 2023 | 1.01 Mn |
| Jun 30, 2023 | -364,000.00 |
| Mar 31, 2023 | -919,000.00 |
| Dec 31, 2022 | -1.54 Mn |
| Sep 30, 2022 | -821,000.00 |
| Jun 30, 2022 | -285,000.00 |
| Mar 31, 2022 | 506,000.00 |
| Dec 31, 2021 | -1.78 Mn |
| Sep 30, 2021 | -795,000.00 |
| Jun 30, 2021 | -1.15 Mn |
| Mar 31, 2021 | 286,000.00 |
| Dec 31, 2020 | 4.83 Mn |
| Sep 30, 2020 | -946,000.00 |
| Jun 30, 2020 | -1.11 Mn |
| Mar 31, 2020 | 173,000.00 |